Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
Medical abortion
| Background | |
|---|---|
| Abortion type | Medical |
| First use | United States 1979 (carboprost), West Germany 1981 (sulprostone), Japan 1984 (gemeprost), France 1988 (mifepristone), United States 1988 (misoprostol) |
| Gestation | 3–24+ weeks |
| Usage | |
| Medical abortions as a percentage of all abortions | |
| France | 76% (2021) |
| Sweden | 96% (2021) |
| UK: Eng. & Wales | 87% (2021) |
| UK: Scotland | 99% (2021) |
| United States | 63% (2023) |
| Infobox references | |
| Combination of | |
|---|---|
| Mifepristone | Progesterone receptor modulator |
| Misoprostol | Prostaglandin |
| Clinical data | |
| Trade names | Mifegymiso,[1] others |
| Routes of administration | Buccal, by mouth |
| ATC code | |
| Legal status | |
| Legal status | |
A medical abortion, also known as medication abortion or non-surgical abortion, occurs when drugs (medication) are used to bring about an abortion. Medical abortions are an alternative to surgical abortions such as vacuum aspiration or dilation and curettage.[6] Medical abortions are more common than surgical abortions in most places around the world.[7][8]
Medical abortions are most commonly performed by administering a two-drug combination: mifepristone followed by misoprostol. This two-drug combination is more effective than other drug combinations.[6] When mifepristone is not available, misoprostol alone may be used in some situations.[9]
Medical abortion is both safe and effective throughout a range of gestational ages, including the second and third trimester.[10][11][12] In the United States, the mortality rate for medical abortion is 14 times lower than the mortality rate for childbirth, and the rate of serious complications requiring hospitalization or blood transfusion is less than 0.4%.[13][14][15][16] Medical abortion can be administered safely by the patient at home, without assistance, in the first trimester.[17] In the second trimester and beyond, it is recommended to take the second drug in a clinic, provider's office, or other supervised medical facility.[17]
- ^ a b Linepharma International Limited (April 15, 2019). "Mifegymiso Product Monograph" (PDF). Health Canada.
- ^ "AusPAR: MS-2 Step (composite pack)". Therapeutic Goods Administration (TGA). February 15, 2024. Retrieved March 31, 2024.
- ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. May 4, 2016. Retrieved April 7, 2024.
- ^ "Medabon - Combipack of Mifepristone 200 mg tablet and Misoprostol 4 x 0.2 mg vaginal tablets - Summary of Product Characteristics (SmPC)". Electronic Medicines Compendium (EMC). February 3, 2020. Retrieved January 19, 2021.
- ^ "Mifepristone/misoprostol: List of nationally authorised medicinal products" (PDF). European Medicines Agency. January 14, 2021. PSUSA/00010378/202005.
- ^ a b Zhang J, Zhou K, Shan D, Luo X (May 2022). "Medical methods for first trimester abortion". The Cochrane Database of Systematic Reviews. 2022 (5): CD002855. doi:10.1002/14651858.CD002855.pub5. PMC 9128719. PMID 35608608.
- ^ Cite error: The named reference
Kapp 2009was invoked but never defined (see the help page). - ^ Jones RK (December 1, 2022). "Medication Abortion Now Accounts for More Than Half of All US Abortions". Guttmacher Institute. Retrieved April 16, 2023.
- ^ Langer BR, Peter C, Firtion C, David E, Haberstich R (2004). "Second and third medical termination of pregnancy with misoprostol without mifepristone". Fetal Diagnosis and Therapy. 19 (3): 266–270. doi:10.1159/000076709. PMID 15067238. S2CID 25706987.
- ^ Vlad S, Boucoiran I, St-Pierre ÉR, Ferreira E (June 2022). "Mifepristone-Misoprostol Use for Second- and Third-Trimester Medical Termination of Pregnancy in a Canadian Tertiary Care Centre". Journal of Obstetrics and Gynaecology Canada. 44 (6): 683–689. doi:10.1016/j.jogc.2021.12.010. PMID 35114381. S2CID 246505706.
- ^ Whitehouse K, Brant A, Fonhus MS, Lavelanet A, Ganatra B (2020). "Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis". Contraception. 2: 100037. doi:10.1016/j.conx.2020.100037. PMC 7484538. PMID 32954250.
- ^ Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. (Cochrane Editorial Unit) (October 2019). "Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions". The Cochrane Database of Systematic Reviews. 10 (10): ED000142. doi:10.1002/14651858.ED000142. PMC 10284251. PMID 31643080.
- ^ Cite error: The named reference
ANSIRH_2019-04was invoked but never defined (see the help page). - ^ Cite error: The named reference
FDA_2018-12-31was invoked but never defined (see the help page). - ^ Cite error: The named reference
C_2012-06-19was invoked but never defined (see the help page). - ^ Cite error: The named reference
NYT_2022-08-07was invoked but never defined (see the help page). - ^ a b Cite error: The named reference
WHO362was invoked but never defined (see the help page).
Previous Page Next Page
